Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Resurrecting ancestral receptors to uncover the origins of drug specificity

EF 2018-19

Résumé
As healthcare improves, the world’s population is aging, and the number of people with age-related cognitive impairment is on the rise. This is creating economic and social burdens on society. Few options exist for treating cognitive impairment, however existing strategies emphasize the importance of cholinergic signaling. Pharmaceutical companies have begun to target acetylcholine receptors (AChRs) on cholinergic neurons as a way to modulate synaptic activity. The most abundant AChR in the brain is the alpha7 AChR. Positive allosteric modulators (PAMs) of alpha7 have been developed to strengthen synaptic response, however little is known about the location of their binding sites, or the residues that mediate their action. We hypothesize that different alpha7 PAMs act through divergent sites in the transmembrane domain. Unlike the acetylcholine binding site, PAM sites are under less evolutionary pressure, and thus tend to be more diverse within homologous proteins. For instance, PNU-120596 (PNU) potentiates mammalian alpha7 AChRs, but has no effect on the C. elegans alpha7 homolog, ACR-16. Using an evolutionary biochemistry approach, this project will replay the evolutionary trajectory of alpha7 in the lab. By resurrecting ancestral alpha7 subunits and testing them in the lab, we will identify evolutionary intervals where sensitivity to a particular PAM arose. We will then identify the amino acids responsible for PAM sensitivity, and the number of PAM molecules required for potentiation. Once complete, this project will deepen our understanding of how PAMs interact with alpha7, and will offer new insight into drug specificity. Ultimately, these results will aid the rational design of small-molecules for treating cognitive diseases through targeting of alpha7 AChRs.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406586
Name
Emlaw Johnathon R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Resurrecting ancestral receptors to uncover the origins of drug specificity
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acetylcholine Receptors; Allosteric Modulators; Evolutionary Biochemistry; Ion Channels; Mechanisms Of Drug Action; Molecular Pharmacology; Neurodegenerate Diseases; Single-Molecule Electrophysiology; Structural Biology; Synthetic Biology
Abstract
As healthcare improves, the world’s population is aging, and the number of people with age-related cognitive impairment is on the rise. This is creating economic and social burdens on society. Few options exist for treating cognitive impairment, however existing strategies emphasize the importance of cholinergic signaling. Pharmaceutical companies have begun to target acetylcholine receptors (AChRs) on cholinergic neurons as a way to modulate synaptic activity. The most abundant AChR in the brain is the alpha7 AChR. Positive allosteric modulators (PAMs) of alpha7 have been developed to strengthen synaptic response, however little is known about the location of their binding sites, or the residues that mediate their action. We hypothesize that different alpha7 PAMs act through divergent sites in the transmembrane domain. Unlike the acetylcholine binding site, PAM sites are under less evolutionary pressure, and thus tend to be more diverse within homologous proteins. For instance, PNU-120596 (PNU) potentiates mammalian alpha7 AChRs, but has no effect on the C. elegans alpha7 homolog, ACR-16. Using an evolutionary biochemistry approach, this project will replay the evolutionary trajectory of alpha7 in the lab. By resurrecting ancestral alpha7 subunits and testing them in the lab, we will identify evolutionary intervals where sensitivity to a particular PAM arose. We will then identify the amino acids responsible for PAM sensitivity, and the number of PAM molecules required for potentiation. Once complete, this project will deepen our understanding of how PAMs interact with alpha7, and will offer new insight into drug specificity. Ultimately, these results will aid the rational design of small-molecules for treating cognitive diseases through targeting of alpha7 AChRs.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Emlaw, Johnathon R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~